Trial of Apremilast for Oral Ulcers in Behcet's Syndrome


Hatemi G. , Mahr A., Ishigatsubo Y., Song Y., Takeno M., Kim D., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.381, no.20, pp.1918-1928, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 381 Issue: 20
  • Publication Date: 2019
  • Doi Number: 10.1056/nejmoa1816594
  • Title of Journal : NEW ENGLAND JOURNAL OF MEDICINE
  • Page Numbers: pp.1918-1928

Abstract

BackgroundThe small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behcet's syndrome. In a phase 2 trial involving patients with Behcet's syndrome, apremilast reduced the incidence and severity of oral ulcers. Data on the efficacy and safety of apremilast in patients with Behcet's syndrome who had active oral ulcers and had not previously received biologic agents are limited.